Atazanavir, ritonavir, lamivudine — Competitive Intelligence Brief

Atazanavir, ritonavir, lamivudine (Atazanavir, ritonavir, lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + NRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (protease inhibitor + NRTI) HIV protease, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Atazanavir, ritonavir, lamivudine (Atazanavir, ritonavir, lamivudine) — Catholic University of the Sacred Heart. This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanavir, ritonavir, lamivudine TARGET	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + NRTI) class)

1. Catholic University of the Sacred Heart · 1 drug in this class